Empavia Tablet 10/5 mg (Empagliflozin, Linagliptin)

Adult dose

The recommended starting dose of this medication is empagliflozin 10 mg and linagliptin 5 mg once daily. If additional blood sugar control is needed and there is tolerance, the dose may be increased to 25 mg/5 mg once daily. The existing dose should be administered and can be taken without regard to meals. The tablet should be swallowed whole. If a dose is missed, it should be taken as soon as remembered, but if the next dose is within 12 hours, skip the missed dose and continue as scheduled.

This medication contains empagliflozin and linagliptin, which are diabetes medications that help with blood sugar control. This medication should not be used in patients with an allergy to empagliflozin, linagliptin, or any other components of this drug. It should not be administered to patients with type 1 diabetes or diabetic ketoacidosis. This drug is not recommended for patients with very poor kidney function or those undergoing dialysis, as well as patients with a history of myocardial infarction. Patients with slightly impaired kidney function should undergo regular kidney function tests before and after taking this medication. It should be used cautiously in patients with congestive heart failure classified as NYHA functional class I-II, and is not recommended for those in classes III-IV. If severe abdominal pain, a symptom of acute pancreatitis, occurs while taking this medication, it should be discontinued immediately and a doctor notified. Additionally, if there are signs of bullous pemphigoid, characterized by the presence of blisters on the skin, the medication should be stopped and a specialist consulted. The most common side effect of this medication is urinary tract infection, which may occur more frequently in women. Symptoms of hypoglycemia may also occur, which can increase when taken with insulin or sulfonylureas; caution is needed. This medication can cause dehydration and low blood pressure; therefore, especially the elderly or those with cardiovascular conditions should be closely monitored for fluid status. Regular monitoring of blood sugar levels and kidney function is advisable during the course of this medication, and any unusual symptoms should prompt immediate consultation with healthcare professionals. It is recommended that pregnant or breastfeeding women do not use this medication and consult a physician if necessary. Safety and efficacy in pediatric patients under 18 years of age have not been established, so it is best not to use in this population. In case of overdose, appropriate treatment such as removing the drug from the gastrointestinal tract is needed, and a medical institution should be visited immediately. This medication should be kept out of reach of children and stored in its original container to maintain quality.

Serious side effects

Hives, angioedema, ketoacidosis, pancreatitis, bullous pemphigoid, urosepsis, pyelonephritis, perineal gangrene (Fournier gangrene), severe allergic reactions, severe skin reactions, dyspnea, severe swelling or urination abnormalities, hepatic abnormalities (jaundice), severe neurological symptoms (headache, seizures, confusion, visual impairment, paralysis), acute kidney injury, acute cholangitis, acute cholecystitis, cholangitis, gallstones, acute gallbladder

Mild side effects

• Urinary tract infection
• vulvovaginitis
• balanitis
• nasopharyngitis
• cough
• constipation
• oral ulceration
• itching
• rash
• hypoglycemia

This medication should be stored in a tightly sealed container to protect it from air and moisture. It is important to maintain a storage temperature between 1 to 30 degrees Celsius at room temperature. This will help ensure the drug's efficacy and safety for a long period.

Appearance

Yellow round film-coated tablet

Package unit

28 tablets/box [14 tablets/PTP x 2], 30 tablets/bottle